1 active not recruiting, 1 completed, 1 enrolling by invitation, 1 recruiting. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 1, Completed 1, Enrolling by invitation 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Completed 1 |
Follow Chang Gung University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Dose-Finding, and Efficacy of Transcranial Pulse Stimulation for Post-Stroke Neurorehabilitation Required Field - Ischemic Stroke | Phase 1 / Phase 2 | Enrolling by invitation | Taipei Hospital, Ministry of Health and Welfare | 9 | 2026-08-20 | 2026-08-25 |
| Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis statin + ezetimibe, Statin monotherapy (rosuvastatin or atorvastatin) - Ischemic Stroke, Hypercholesteremia | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 300 | 2025-08-01 | 2025-12-30 |
| Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis Alirocumab - Intracranial Atherosclerosis, Acute Ischemic Stroke | Phase 2 | Active not recruiting | Chang Gung Memorial Hospital | 60 | 2021-08-01 | 2025-03-26 |
| Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome SS-1, Placebo - Sjögren's Syndrome | Phase 2 | Unknown | Chang Gung Memorial Hospital | 60 | 2014-02-01 | 2016-02-02 |
| Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis Indigo Naturalis Extract in Oil, Calcipotriol Solution - Nail Psoriasis | Phase 2 / Phase 3 | Completed | Yin-ku Lin | 33 | 2011-01-01 | 2019-09-10 |
Ischemic Stroke (3) · Hypercholesterolemia (1) · Intracranial Arteriosclerosis (1) · Sjogren's Syndrome (1)
Atorvastatin (1) · Ezetimibe (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Oils (1) · Rosuvastatin Calcium (1) · alirocumab (1) · calcipotriene (1) · sang ju yin (1)
Taiwan (5)
Hen-Hong Chang, M.D., Ph.D. (1) · Yenchu Huang, MD (1) · Yin-Ku Lin, M.D., Ph.D. (1)